**Funding**

This manuscript is not funded. Dr. Ntusi gratefully acknowledges support from the American Heart Association, the National Institutes of Health/National Heart, Lung, and Blood Institute, National Research Foundation and the Medical Research Council of South Africa, as well as the Harry Crossley Foundation.

[5] Hakim JG, Matenga JA, Siyiza S. Myocardial dysfunction in human immunodeficiency virus infection: An echocardiographic study of 157 patients in hospital in Zimbabwe.

HIV-Associated Cardiovascular Disease http://dx.doi.org/10.5772/intechopen.80483 195

[6] Ntsekhe M, Mayosi BM. Cardiac manifestations of HIV infection: An African perspec-

[7] Magula N, Mayosi BM. Cardiac involvement in HIV-infected people living in Africa: A

[8] Ntsekhe M, Hakim J. Impact of human immunodeficiency virus infection on cardiovas-

[9] Friis-Møller N, Thiébaut R, Reiss P, Weber R, Monforte AD, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: The data collection on adverse effects of anti-HIV drugs study. European Journal of Cardiovascular Prevention and

[10] Sliwa K, Carrington MJ, Becker A, Thienemann F, Ntsekhe M, Stewart S. Contribution of the human immunodeficiency virus/acquired immunodeficiency syndrome epidemic to de novo presentations of heart disease in the heart of Soweto study cohort. European

[11] Hsue PY, Hunt PW, Ho JE, Farah HH, Schnell A, et al. Impact of HIV infection on diastolic function and left ventricular mass. Circulation. Heart Failure. 2010;**3**(1):132-139

[12] Longo-Mbenza B, Seghers LV, Vita EK, Tonduangu K, Bayekula M. Assessment of ventricular diastolic function in AIDS patients from Congo: A Doppler echocardiographic

[13] Lipshultz SE, Easley KA, Orav EJ, Kaplan S, Starc TJ, et al. Cardiac dysfunction and mortality in HIV-infected children: The prospective P2C2 HIV multicenter study. Pediatric pulmonary and cardiac complications of vertically transmitted HIV infection (P2C2 HIV) study

[14] Al-Kindi SG, ElAmm C, Ginwalla M, Mehanna E, Zacharias M, et al. Heart failure in patients with human immunodeficiency virus infection: Epidemiology and management

[15] Ntusi NAB, Ntsekhe M. Human immunodeficiency virus-associated heart failure in sub-Saharan Africa: Evolution in the epidemiology, pathophysiology, and clinical mani-

[16] Cerrato E, D'Ascenzo F, Biondi-Zoccai G, Calcagno A, Frea S, et al. Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: A meta-analysis in the highly active antiretroviral therapy era. European Heart Journal. 2013;**34**(19):1432-1436

[17] Onur I, Ikitimur B, Oz F, Ekmekci A, Elitok A, et al. Evaluation of human immunodeficiency virus infection-related left ventricular systolic dysfunction by tissue Doppler

festations in the antiretroviral era. ESC Heart Failure Journal. 2016;**3**(3):158-167

disparities. International Journal of Cardiology. 2016;**218**:43-46

strain echocardiography. Echocardiography. 2014;**31**(10):1199-1204

tive. Nature Clinical Practice. Cardiovascular Medicine. 2009;**6**(2):120-127

review. Cardiovascular Journal of South Africa. 2003;**14**(5):231-237

cular disease in Africa. Circulation. 2005;**112**(23):3602

Heart. 1996;**76**(2):161-165

Rehabilitation. 2010;**17**(5):491-501

Heart Journal. 2012;**33**(7):866-874

study. Heart. 1998;**80**(2):184-189

group. Circulation. 2000;**102**(13):1542-1548
